Pembrolizumab in a combination with chemotherapy improves the general survival at application in the first line at patients with NMRL which have no PD-L1 expression in a tumor

@
Show original
08.10.2019 - Company MSD reported that pembrolizumab in a combination with chemotherapy (HT) showed improvement of the general survival (GS), the survival without progressing (SWP) and the frequency of objective answers (FOA) at patients with a widespread nemelkokletochny cancer of easy (NMRL) without PD-L1 expression in a tumor (TPS...

Full article is available at its source

Go to full article
Open the Connections Tree and see if United States of... and are connected in any way
Try it

Sign up for more features!

Get full access to news analytics for free and without ads.

Article analysis

×
Persons
in this article
Zakirova Lilia
Organizations
in this article